Kıyıcı, AyselMehmetoğlu, İdrisKaraoğlan, HaticeAtalay, HüseyinSolak, YalçınTürk, Süleyman2020-03-262020-03-262010Kıyıcı, A., Mehmetoğlu, İ., Karaoğlan, H., Atalay, H., Solak, Y., Türk, S., (2010). Ischemia-Modified Albumin Levels in Patients with End-Stage Renal Disease Patients on Hemodialysis: Does Albumin Analysis Method Affect Albumin-Adjusted Ischemia-Modified Albumin Levels?. Journal of Clinical Laboratory Analysis, 24(4), 273-277. DOI 10.1002/jcla.203990887-80131098-2825https://dx.doi.org/10.1002/jcla.20399https://hdl.handle.net/20.500.12395/25027Ischemia-Modified albumin (IMA) has been used as an early marker in the evaluation of the patients with acute coronary syndrome. We aimed to evaluate IMA in end-stage renal disease (ESRD) patients on hemodialysis and the effect of albumin methods on albumin-adjusted IMA levels. A total of 30 ESRD patients were included in this study. Serum IMA and albumin levels were measured before and after a hemodialysis session. Albumin concentrations were determined with bromocresol green and bromocresol purple methods. Postdialysis IMA and albumin-adjusted IMA levels with two different albumin methods were significantly increased compared with the predialysis levels (P<0.05). However, we did not find any difference in albumin-adjusted IMA levels in either at the beginning or at the end of the dialysis session. IMA levels increase after hemodialysis, whereas albumin method has no effect on albumin-adjusted IMA levels.en10.1002/jcla.20399info:eu-repo/semantics/openAccessIschemia-Modified albuminBromocresol greenBromocresol purpleend stage renal diseasehemodialysisArticle24427327720626021Q1WOS:000283412000011Q3